Company: SCLXW
Filing Date: 2025-11-04
Form Type: 424B3
Source: 0001193125-25-264325
Chunk: 23

Company: Scilex Holding Co
Filing Date: 2025-11-04
Form: 424B3
Chunk 23
---
 representation of the Licensor in matters not substantially related to this Agreement, and the Licensor gives its informed consent to Paul Hastings LLP’s representation of the Licensee in connection with this Agreement and the transactions contemplated hereby.

<div align='center'>License Agreement32Datavault AI Inc.</div>

The undersigned Parties have carefully reviewed this Agreement and accept its terms and conditions. The Parties execute this Agreement as of its Effective Date.

| LICENSOR:                  | LICENSEE:                      |
| Datavault AI Inc.          | Scilex Holding Company         |
| By: /s/ Nate Bradley       | By: /s/ Henry Ji               |
| Printed Name: Nate Bradley | Printed Name: Henry Ji, Ph.D.  |
| Title: CEO                 | Title: Chief Executive Officer |

<div align='center'>License Agreement33Datavault AI Inc.</div>

Exhibit 99.1

FOR IMMEDIATE RELEASE

November 4, 2025

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from DataVault AI

PALO ALTO, CALIFORNIA – November 4, 2025 (GLOBE NEWSWIRE) -Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has in-licensed a worldwide exclusive license, with right to sublicense, to DataVault AI’s proprietary AI-driven technology for the use within the biotech and biopharma industry, specifically enabling the creation and operation of a Biotech Exchange platform. This license allows Scilex to leverage Datavault AI's advanced data platforms for secure tokenization, trading, and monetization of biotech assets, including genomic, DNA data, diagnostic, therapeutic products, genetic and drug information, marking a significant step forward in the commercialization of biotech innovations.

Scilex also believes that this advanced data platform will have the potential to expand into the creation of a Pharmaceutical Exchange platform which will potentially revolutionize the entire pharmaceutical industry.

Scilex believes that there is an opportunity to tokenize approximately $2.0 trillion dollars pharmaceutical drug sales and diagnostic sales.1Scilex